Skip to main content
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. — Investor Relations & Filings

Ticker · CRDL TSX Professional, scientific and technical activities
Open in API
Filings indexed 257 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country CA Canada
Listing TSX CRDL

About Cardiol Therapeutics Inc.

https://www.cardiolrx.com/

Cardiol Therapeutics Inc. is a clinical-stage life sciences company dedicated to the research and clinical development of disease-modifying therapies for heart disease. The company focuses on developing anti-inflammatory and anti-fibrotic treatments designed to target the underlying mechanisms contributing to cardiac conditions. Its therapeutic pipeline, currently in clinical trials, addresses underserved heart diseases, including rare cardiac conditions such as Pericarditis and Myocarditis, as well as Heart Failure (Heart Failure with preserved ejection fraction (HFpEF) and Heart Failure with reduced ejection fraction (HFrEF)). The company leverages international research collaborations to advance its novel therapeutic approaches.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing a live interview with the company’s CEO on an external platform. It contains forward-looking statements, company background, and event details – but it is not an earnings release, financial report, regulatory proxy, or formal filing. It does not present results, governance changes, MD&A, or a transcript. It is a general announcement of an investor-relations event, which does not fit any specific category, so it falls under the fallback Regulatory Filings category (RNS).
2026-04-14 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing an upcoming live interview about clinical trial updates and does not present financial results, an earnings release, a report, or any of the other specialized categories. It contains forward-looking statements but is not a formal report or filing itself. Therefore it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-14 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a notice of the upcoming Annual General Meeting and record dates filed via SEDAR+ to exchanges and securities administrators. It does not contain proxy materials themselves, results of voting, or financial data—it is purely a regulatory announcement of the meeting details. No other category (e.g., AGM presentation, proxy circular, voting results) fits this form, so the fallback category Regulatory Filings (RNS) is appropriate.
2026-04-10 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal “Notice of Meeting and Record Date” for an upcoming Annual General Meeting, outlining meeting type, dates, record dates, and proxy delivery arrangements. This notice is part of the materials provided to shareholders to inform them of the meeting and solicit their votes. Therefore it falls under Proxy Solicitation & Information Statement (PSI).
2026-04-10 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a year-end operational update press release from Cardiol Therapeutics following the filing of its audited financial statements and MD&A. It provides a broad corporate update including clinical trial progress, patent allowances, board appointment, and financing, but it does not present full financial results like an earnings release, nor is it the actual annual report (10-K) or MD&A. It is not a pure report publication announcement (RPA) since it contains substantive operational highlights, and does not fit into any specific category like M&A, dividends, or governance. Hence, it falls into the general regulatory announcement fallback category: RNS.
2026-04-01 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate news release providing a year-end operations update – summarizing clinical trial milestones, patent allowances, board election, and financing – and merely noting that audited financial statements and MD&A have been filed and are available online. It does not present detailed financial results (no revenues, EPS, or balance sheet data), nor is it the actual annual or interim report, management discussion & analysis, or investor presentation itself. It also isn’t focused solely on a financing or board change. This makes it a general regulatory announcement without a narrower fitting category.
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.